Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 21, 2021

View Archived Issues

FDG-PET signal is substantially affected by microglial glucose uptake in neurodegenerative diseases

New spondyloarthritis therapeutic target identified

Elevated plasma CXCL16 levels found in severe COVID-19 patients

LRFN1 gene as a possible cause of autism spectrum disorder

Discovery of broad-spectrum inhibitor of oncogenic BRAF dimerization

Role of de novo mutations in severe male infertility

Hutchison MediPharma patents new CSF1R inhibitors

Chinese researchers disclose new ROS inhibitors

Whole exome sequencing analysis identifies novel genes associated with osteoarthritis

Angiex presents new TM4SF1-targeting PROTACs

Dongguan Hec New Drug Research and Development synthesizes new HBV antivirals

Medshine Discovery describes new compounds for cancer

Alu RNA induces retinal pigment epithelium degeneration in geographic atrophy via the inflammasome

Mitochondrial augmentation: a promising disease-modifying strategy for mitochondrial DNA disorders

NPAS3 identified as a risk gene for autism spectrum disorder

Tango Therapeutics' MTAPnull PRMT5 inhibitor TNG-908 active in multiple xenograft tumor models

HLA fine mapping identifies INPP5A as a risk gene for tuberculosis

Oncodesign and TiumBio collaborate to discover and develop candidates for fibrosis

Mablink and Emergence enter licensing agreement for ADC targeting Nectin-4

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...